|
5th Conference on Retroviruses and Opportunistic InfectionsChicago, IL - February 1-5, 1998 |
Cite as: Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:Abstract No. xx
| Session 1— Opening Session |
||
| S1 | Memorial Lecture: Measures of reality. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S1) Haase AT; University of Minnesota, Minneapolis, MN |
|
| S2 | Keynote Lecture: The challenge of making an AIDS vaccine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S2) Baltimore D; Caltech, Pasadena, CA |
|
| Session 2— State-of-the-Art Lecture HIV-1 Entry into Cells: Targets for Drug and Vaccine Development |
||
| L1 | HIV-1 Entry into Cells: Targets for Drug and Vaccine Development Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L1) Sodroski J, Kwong PD, Wyatt R, Desjardins E, Sweet R, Robinson J, and Hendrickson W |
|
| Session 3— State-of-the-Art Lecture Monitoring the Epidemic of HIV/AIDS in the U.S.: Current Status and Future Prospects |
||
| L2 | Epidemiologic Trends Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L2) De Cock KM |
|
| Session 4— State-of-the-Art Lecture Immunopathogenesis of Primate Immunodeficiency Virus Interactions |
||
| L3 | Immunopathogenesis of Primate Immunodeficiency Virus Interactions Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. L3) |
|
| Session 5— Slide Antiretroviral Chemotherapy I |
||
| 1 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF LAMIVUDINE (3TC) IN COMBINATION WITH ZIDOVUDINE (ZDV), STAVUDINE (D4T), OR DIDANOSINE (DDI) IN TREATMENT NAÏVE PATIENTS Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 1) DR Kuritzkes, IC Marschner, VA Johnson, RL Bassett, JJ Eron, MA Fischl, GJ Boone, J Skovronski, K Wood, DL Bell, CB Pettinelli, JP Sommadossi 299 antiretroviral-naïve subjects with HIV-1 infection and CD4 counts of 200-600 cells/mm3 were randomized to either a d4T or ddI limb and then randomized in a blinded fashion to one of three arms within each limb (d4T limb: d4T alone, d4T/3TC, or ZDV/3TC; ddI limb: ddI alone, ddI/3TC, or ZDV/3TC). | |
| 2 | COMBINATION ZIDOVUDINE (ZDV) AND STAVUDINE (D4T) THERAPY VERSUS OTHER NUCLEOSIDES: REPORT OF TWO RANDOMIZED TRIALS (ACTG 290 AND 298) Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 2) DV Havlir, G Friedland, R Pollard, C Tierney, L Smeaton, L Fox, DD Richman and the ACTG 290/298 Teams These data suggest a) ZDV/d4T does not have more potent antiviral effect than d4T alone, probably due to pharmacologic antagonism. ZDV/d4T is associated with CD4 cell decline in ZDV experienced patients. ZDV/d4T therefore should not be used in combination; b) ddI produces greater viral suppression than d4T in ZDV experienced patients; c) ZDV/ddI was not associated with virologic activity discernable from ddI in ZDV experienced patients. |
|
| 3 | IMPAIRMENT OF STAVUDINE (d4T) PHOSPHORYLATION IN PATIENTS RECEIVING A COMBINATION OF ZIDOVUDINE (ZDV) AND d4T (ACTG 290) Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 3) JP Sommadossi, XJ Zhou, J Moore, DV Havlir, G Friedland, C Tierney, L Smeaton, F Fox, D Richman, R Pollard R In one patient who received the d4T/ZDV comb for 42 weeks and subsequently a d4T monotherapy for 8 weeks, no d4T-TP was detected at 2, 4 and 6 weeks following ZDV discontinuation. These data suggest that in patients receiving a comb of ZDV/d4T, the intracellular phosphorylation of d4T to d4T-TP is hampered and this negative effect may be prolonged for several weeks after discontinuation of ZDV treatment. |
|
| 4 | ANTIRETROVIRAL EFFECTS OF THERAPY COMBINING ABACAVIR (1592) WITH HIV PROTEASE INHIBITORS (PIS) Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:79 (abstract no. 4) Mellors J, Lederman M, Haas D, Horton J, Haubrich R, Stanford J, Cooney E, McMahon D, Spreen W, Smiley M, Kelleher D Abacavir (300 mg, ql2h) in dual combination with 5 different PIs was well tolerated and demonstrated potent antiretroviral activity. |
|
| 5 | Abstract Withdrawn | |
| 6 | PRELIMINARY ASSESSMENT OF 141W94 IN COMBINATION WITH OTHER PROTEASE INHIBITORS Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 6) Eron J, Haubrich R, Richman D, Lang W, Tisdale M, Myers R, Pagano G, Rogers M During the initial 4 weeks of this study, the combinations were generally well tolerated and had significant antiviral activity. Continued investigation of these combinations is ongoing. |
|
| 7 | IN VITRO AND IN VIVO ACTIVITY OF ANTI-RETROVIRAL COMPOUNDS ATTACKING NC ZINC FINGERS Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 7) Henderson LE, Chertova E, Ott D, Hewes SM, Cases-Finet JR, Kane B, Johnson DG, Sowder II RC, Rossio J, Lifson J, Arthur LO These results show that at least one compound has been identified which has an enhanced reactivity with the target NC protein, inactivates whole virus (SIV, HIV-1 and MuLV), react selectively with the whole viral NC protein, is non-toxic, can be taken orally and reduces viral replication in the MuLV/mouse model and in the SIV/monkey model. These results strongly support the suggestion that the reactivity of the NC protein CCHC ZFs can be exploited to develop a new class of anti-retroviral compounds that may find therapeutic applications. |
|
| 8 | AVANTI 3. A RANDOMISED, DOUBLE BLIND, COMPARATIVE TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERANCE OF AZT/3TC VS AZT/3TC/NELFINAVIR IN ANTI-RETROVIRAL NAÏVE PATIENTS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 8) Clumeck N Both treatment groups demonstrated improvement in viral load over the 28 week period and AUCMB analysis demonstrated a statistically significant reduction in viral load over same timeframe for AZT/3TC/nelfinavir as compared to AZT/3TC. Further data on CD4 and safety will also be presented. |
|
| Session 6— Slide Epidemiology |
||
| 9a | IMPROVED SURVIVAL TIME AFTER DIAGNOSIS WITH AIDS AMONG ADULTS IN NEW YORK CITY (NYC), 1980-1994 Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 9a) Muthambi BR, Chiasson MA, Lehner T, Singh TP Survival time improved consistently with each successive time period of diagnosis and across all groups assessed. |
|
| 9b | ACCELERATING DECLINE IN NEW YORK CITY AIDS MORTALITY Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 9b) Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, Mojica B The dramatic decline in AIDS deaths first observed in NYC in 1996 continued through the 1st half of 1997 in all demographic groups. This occurred at a time when new antiretroviral therapy became widely available. |
|
| 10 | THE EFFECTS OF ANTIRETROVIRAL THERAPY AND OPPORTUNISTIC ILLNESS PRIMARY CHEMOPROPHYLAXIS ON SURVIVAL AFTER AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 10) McNaghten AD, Hanson DL, Jones JL, Ward JW, Dworkin MS The risk of death is 2.5 times lower for persons receiving triple ART than persons receiving monotherapy. These results provide early indication of the beneficial effects of protease inhibitors on survival in an observational study. Additionally, we found that PCP and MAC prophylaxis and pneumococcal vaccination have positive effects on survival. |
|
| 11 | Beyond clinical trials--population-based HIV viral load monitoring and antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 11) Denning P, Fleming P These data demonstrate the benefits of PI therapy in minimizing VL in the general population of HIV-infected persons. However, 53% of persons reported with HIV/AIDS in 1997 on these areas had not received VL testing; and of those who had, 42% had not received ARV therapy despite advanced HIV disease. |
|
| 12 | Longitudinal plasma HIV RNA patterns among HIV-1 infected individuals with late disease progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 12) Gange SJ, Mellors JW, Schrager L, Margolick JB, Giorgi JV, Detels R, Phair J, Munoz A &&&Johns Hopkins School of Public Health, Baltimore, MD |
|
| 13 | HIV-1 is actively produced in the female genital tract. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 13) Lennox JL, Ellerbrock TV, Schinazi RF, Clancy K, Pratt-Palmore M, Bush T, Hough L, Schnell C, Hart C &&&Emory University, Atlanta, GA |
|
| 14 | Risk factors for unprotected sex among men reported with AIDS in Los Angeles County: implications for HIV prevention. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 14) Simon P, Thometz E, Bunch G, Sorvillo F, Detels R &&&Centers for Disease Control and Prevention, Atlanta, GA |
|
| 15 | A peer education intervention reduces HIV infection among factory workers in Zimbabwe. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:81 (abstract no. 15) Machekano R, Mcfarland W, Mzezewa V, Ray S, Mbizvo M, Bassett M, Latif A, Mason P, Gwanzura L, Moses L, Ley C, Brown B, Parsonnet J, Katzenstein D &&&Stanford University Medical Center, Stanford, CA |
|
| 16 | The efficacy of counseling and testing in reducing HIV risk in developing countries: a three-country randomized controlled trial. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 16) Coates TJ; University of California, San Francisco, CA |
|
| Session 7— Slide Immunopathogenesis of HIV-1 Infection |
||
| 17 | Analysis of TCR repertoire against a conserved HIV-RT CTL epitope in a cohort of HIV+ patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 17) Kolowos W, Bachmann O, Schmitt M, Herrmann M, Goldwich A, Baurle M, Low P, Harrer E, Kalden JR, Harrer T &&&Department of Medicine III, University of Erlangen-Nurnberg, Germany |
|
| 18 | Abnormal T cell receptor repertoire in children with vertically-acquired HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 18) McFarland EJ, Harding PA, Striebich CC, Kuritzkes DR, Kotzin BL; University of Colorado Health Science Center, Denver, CO |
|
| 19 | Antiretroviral drug-mediated suppression of HIV-1 results in loss of CD8+ T cell receptor (TCR) skewing and reduced frequency of epitope-specific CD8+ Cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 19) Gray CM, Schapiro JM, Altman J, Lawrence J, Crompton M, Merigan TC; Stanford University, Stanford, CA |
|
| 20 | Immunological reconstitution after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:82 (abstract no. 20) Miedema F, Pakker NG, Notermans DW, De Boer R, Kostense S, Roos MT, De Wolf F, Hill A, Leonard JM, Danner SA, Raaphorst FM, Schellekens PT &&&Academic Medical Centre, University of Amsterdam, The Netherlands |
|
| 21 | Immunologic changes in blood and lymph nodes induced by highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 21) Hicks CB, Markert L, Ottinger J, Ferrari G, Harmon L, Demarest J, Bartlett JA, Hale L, Weinhold K &&&Duke University Medical Center, Durham, NC |
|
| 22 | Increased turnover of CD4 and CD8 T cells in untreated HIV infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 22) Sachsenberg N, Perelson A, Perrin L &&&Laboratory of Virology, University Hospital, Geneva, Switzerland |
|
| 23 | M-tropic HIV-1 strains are extremely sensitive to inhibition by RANTES. Sensitivity of T-tropic strains to RANTES is donor cell dependent. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 23) Trkola A, Vesanen M, Monard S, Siani MA, Hoxie JA, Wu L, Moore JP; Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY |
|
| 24 | Anergy and dysfunction of CD4+ and Vgamma 2Vdelta 2+ lymphocytes associated with Mycobacterium bovis BCG-induced disease in SIV-infected monkeys. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 24) Zhou Z, Lee-Parritz D, Chalifoux L, Simon M, Morita CT, Letvin NL, Chenz ZW &&&Beth Israel Deaconess Medical Center, Boston, MA |
|
| Session 8— Slide Virology I |
||
| 25 | A novel human protein that interacts with HIV-1 Vpu, connects CD4 to the ER degradation pathway. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:83 (abstract no. 25) Margottin F, Bour SP, Durand H, Strebel K, Benarous R &&&INSERM, ICGM, Paris, France |
|
| 26 | HIV-1 Vpr enters the nucleus via a novel import pathway. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 26) Jenkins Y, McIntee M, Kuo A, Weis K, Greene WC |
|
| 27 | The putative alpha helix 2 of HIV-1 Vpr contains a determinant which is responsible for the translocation of the proviral DNA in growth-arrested cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 27) Cohen EA, Subbramanian RA, Nie Z, Yao XJ, Rougeau N, Bergeron D |
|
| 28 | Co-operative interaction of V(1)-V(2) region with V(3) region of HIV-1 gp120 is important for productive viral infection: its role in binding of gp120 to viral co-receptor. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 28) Chen M, Gupta PA |
|
| 29 | Vpr is the key regulator of HIV-1 nuclear import. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 29) Bukrinsky M, Popov S, Zybarth G |
|
| 30 | NC protein role in selective HIV-1 genomic RNA packaging. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 30) Poon DT, Li G, Aldovini A |
|
| 31 | Trans complementation of integrase function. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:84 (abstract no. 31) Soares MA, Weng Z, Wakefield J, Mcphearson S, Shaw GM, Leavitt AD, Boeke JD, Hahn BH |
|
| 32 | Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 32) Arion D, Borkow G, Kaushik N, Parniak MA |
|
| Session 9— Symposium Chemokine Receptors and HIV/SIV |
||
| S3 | The effect of polymorphisms in the regulatory regions of the CCR5 promoter on HIV-1 vertical transmission and on disease progression in infected children. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S3) Moore JP, Kostrikis LG, Ho DD |
|
| S4 | Infection of macrophages by primary, syncytium-inducing HIV-1 strains: the role of CCR5, CXCR4 and other coreceptors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:229 (abstract no. S4) Clapham PR, Simmons G |
|
| S5 | Structure of Function of CCR2 and CCR5: Molecular Mechanisms of Directed Cell Migration Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S5) Charo I |
|
| S6 | Unwelcome guests with master keys: how HIV-1 used chemokine receptors to infect cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S6) Dorns RW |
|
| Session 10— Symposium AIDS Malignancies |
||
| S7 | Recent Advances in AIDS Malignancies Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S7) Ellen Feigal Abstract not submitted |
|
| S8 | HPV and anogenital cancer: Interaction with HIV Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:230 (abstract no. S8) Lowy DR, Schiller JT |
|
| S9 | Epstein-Barr virus and lymphoma in patients with HIV Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S9) Ambinder RF |
|
| S10 | Malignancies in HIV-infected children Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S10) Mueller BU |
|
| Session 11— Symposium Advances in HIV Prevention |
||
| S11 | Prevention of perinatal HIV transmission. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S11) Mofenson L |
|
| S12 | The use of post-exposure therapy (PET) to prevent non-occupational transmission of HIV. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:231 (abstract no. S12) Smith DK |
|
| S13 | Rapid test strategies for HIV testing. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S13) Branson BM and Janssen R |
|
| S14 | Prevention successes in Thailand's HIV/AIDS prevention. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:232 (abstract no. S14) Wiput Phoolcharoen |
|
| Session 12— Poster Chemokines and Their Receptors |
||
| 33 | Selective exclusion of HIV coreceptors from HIV virions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 33) Bastiani L, Laal S, Hoxie JA, Zolla-Pazner S, Bandres JC |
|
| 34 | Characterization of HIV-1 susceptibility and co-receptor expression of herpesvirus saimiri (HVS) immortalized CD4+ cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 34) Mosoian A, Klotman ME |
|
| 35 | The inability of HIV-1 to infect highly purified CD25-CD4+ T lymphocytes is not due to lack of co-receptor expression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 35) Van Dyke G, Ramilo O, Vitetta ES |
|
| 36 | HIV-1 co-receptor expression is insufficient for infection of hematopoietic stem cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:85 (abstract no. 36) Shen H, Cheng T, Yang O, Golan D, Preffer FI, Luster AD, Scadden DT |
|
| 37 | GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry in human monocytes and macrophages. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 37) Di Marzio P, Mariani R, Tse J, Thomas EK, Landau NR |
|
| 38 | Macrophage replication kinetics of SI and NSI clinical isolates using diverse co-receptors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 38) Lathey JL, Brambilla D, Notka M, Rasheed S, Siwak E, Goodenow M, Bremer JW, Ladd B, Collman R, Reichelderfer P &&&NIAID, Bethesda, MD |
|
| 39 | Modulation of CCR5 expression on macrophages infected with HIV-1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 39) Peng G, Hale-Donze H, Wild T, Orenstein JM, Wahl SM |
|
| 40 | Increased surface expression of CCR5 on monocyte-derived macrophages mediates enhanced susceptibility to HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 40) Tuttle DL, Harrison JK, Sleasman JW, Goodenow MM |
|
| 41 | Role of T-tropic HIV-1 V(3) loop in viral entry into cells analyzed with 3 different anti-CXCR-4 monoclonal antibodies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 41) Hori T, Sakaida H, Hattori T, Sato A, Nakajima T, Shida H, Yoshie O, Uchiyama T |
|
| 42 | Role of CXCR-4, CCR5 and CCR3 in the differential tropism of HIV-1 isolates for distinct thymocyte subsets. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:86 (abstract no. 42) Martins LP, Gurney K, Connors C, Torbett B, Uittenbogaart C |
|
| 43 | HIV-1 replication is substantially supported in rabbit cells expressing human CCR5 and human CD4. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 43) Speck RF, Penn ML, Wimmer J, Esser U, Kindt TJ, Atchison RE, Goldsmith MA |
|
| 44 | Entry and cytopathicity of FIV in human cells is mediated by the CXCR4 chemokine receptor. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 44) Poeschla E, Looney DJ |
|
| 45 | Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: type 1 cytokine upreguation of CCR5 mRNA expression can be abolished by IL-10. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 45) Patterson BK, Czerniewski MA, Andersson J, Felice SU, Landay A |
|
| 46 | Genomic organization and functional characterization of CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 46) Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Michael NL |
|
| 47 | Flow cytometric analysis of the binding of HIV envelope to CXCR4, relevance of the interaction with soluble CD4 and HIV envelope glycosylation. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 47) Bandres JC, Wang QF, O'Leary J, Hoxie JA, Zolla-Pazner S, Gorny MK |
|
| 48 | CCR5 co-receptors derived from nonhuman primates and their usage by SIV, HIV-1 and HIV-2 primary strains. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:87 (abstract no. 48) Kunstman K, Wolinsky S, Agy M, Shibata R, Yoder A, Jones M, Marx P, Chen Z |
|
| 49 | Alpha and beta chemokines exert opposing effects on HIV-GP120-induced B lymphocyte functions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 49) Patke C, Green C, Shearer W |
|
| 50 | Characterization of a panel of anti-CXCR4 monoclonal antibodies. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 50) Turner JD, Willet BJ, Peiper SJ, Endres MJ, Hoxie JA |
|
| 51 | HIV pathogenesis in human lymphoid tissues ex vivo. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 51) Glushakova S, Grivel JC, Fitzgerald W, Yin S, Hatfill S, Sylwester A, Zimmerberg J, Murphy P, Margolis LB |
|
| Session 13— Poster Effects of Chemokine Receptors on Natural History |
||
| 52 | Viral and immunological features and CCR-5 polymorphism in HIV-1 infected long-term non progressors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 52) Galli M, Balotta C, Clementi M, Clerici M |
|
| 53 | HIV-1 qasispecie in a HIV-1 infected patient homozygous for Δ32 deletion of the CCR5 chemokine receptor gene. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:88 (abstract no. 53) Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Papagno L, Sampaolesi R, Riva C, Mazzola F, Berlusconi A, Corvasce S, Clementi M, Galli M, Moroni M |
|
| 54 | The joint effects of chemokine receptor (CCR) variants, plasma HIV RNA (RNA) and CD4+ cells on HIV progression in hemophiliacs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 54) Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots K, Chernoff D, O'Brien SJ |
|
| 55 | Lack of evidence for a role of the &Delta32; deletion mutation in disease progression in HIV infected injection drug users. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 55) Schinkel CJ, Langendam MW, Coutinho RA, Brouwer M, Schuitemaker H |
|
| 56 | Significantly lower plasma viral load in long term slow progressors heterozygous for &Delta32;-CCR5. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 56) Walli R, Reinhart B, Muhlhofer A, Lederer E, Loch O, Gurtler L, Schlondorff D, Goebel FD |
|
| 57 | Co-receptor usage, viral phenotype, and V(3) sequences of HIV-1 isolates obtained from long-term infected hemophilic patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 57) Picchio G, Sabbe R, Boggiano C, Mosier DE |
|
| 58 | Patterns of HIV-1 evolution in vivo and phenotypic specificity correlate with disease progression and the loss of T cell homeostasis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 58) Shankarappa R, Margolick JB, Farzadegan H, Gange S, Gupta P, Rinaldo CR, Upchurch D, Rodrigo AG, Mullins JI |
|
| 59 | Exclusive and persistent use of the entry co-receptor CXCR4 by HIV-1 from a subject homozygous for CCR5 &Delta32;. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:89 (abstract no. 59) Michael NL, Nelson JA, Kewalramani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, Littman DR, Swanstrom R, O'Brien TR |
|
| 60 | A second mutation associated with the CCR5 Δ32 deletion in Δ32-heterozygous individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 60) Aikhionbare F, Newman C, Roth W, Bond C, Stringer G Jr |
|
| 61 | Maintenance of chemokine receptor expression on peripheral and central lymphocytes in human immunodeficiency virus-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 61) Penn ML, Speck RF, Abbey N, Wieder E, Loftus R, Deeks S, Hernder B, Goldsmith MA |
|
| 62 | Expression of chemokine receptors CXCR4 and CCR5 in HIV-1 infected and uninfected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 62) Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell LB, Kumar PN, Mican J, Fauci AS |
|
| Session 14— Poster Viral and Host Determinants of the Natural History of Retroviral Infection |
||
| 63 | Virological study of HIV-1-infected long term asymptomatic subjects (ALTs). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 63) Candotti D, Costagliola D, Rouzioux C, Autran B, Agut H |
|
| 64 | Does cell-associated infectious HIV-1 viral load predict HIV-1 disease progression independently of plasma HIV-1 RNA levels? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:90 (abstract no. 64) Lyles C, Farzadegan HI, Astemborski J, Quinn T, Hoover D, Masters B, Margolick J, Vlahov D |
|
| 65 | The natural history of viral load over 16 years of HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 65) Sabin CA, Devereux H, Phillips AN, Hill AM, Lee CA, Loveday C |
|
| 66 | Emergence of syncytium-inducing HIV-1 variants coincides with burst in viral RNA level and is an independent predictor for progression to AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 66) Spijkerman IJ, de Wolf F, Langendam MW, Schuitemaker H, Coutinho RA |
|
| 67 | Evolution of HIV-1 env sequences in plasma and peripheral blood lymphocytes from subjects with nonprogressive and progressive infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 67) Bagnarelli P, Mazzola F, Sampaolesi R, Menzo S, Clementi M |
|
| 68 | Comparison of nef alleles from PBMC-associated proviral DNA and plasma virion RNA in a cohort of progressors and LTNP hemophiliacs. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 68) Vicenzi E, Turchetto L, Brambilla A, Santagostino E, Clementi M, Poli G, Bagnarelli P |
|
| 69 | Cytopathicity of biological clones isolated from HIV-1 infected patients with intact and depleted CD4 T cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 69) Forte SE, Somasundaran M, Sullivan JL |
|
| 70 | HIV-1 cell tropism, viral RNA levels, and rate of CD4 T cell loss in human PBL-SCID mice. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:91 (abstract no. 70) Mosier DE, Gulizia RJ, Sabbe R, Picchio GR &&&Scripps Research Institute, La Jolla, CA |
|
| 71 | Neutralising antibodies and specific anti-Env and anti-pol IgG1 levels are correlated to HIV-1 replication in long term non progressors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 71) Ngo-Giang-Huong N, Candotti D, Goubar A, Costagliola D, Agut H, Autran B, Rouzioux C |
|
| 72 | Comparison of HIV-1 infected long-term nonprogressors and average progressors in HIV-specific CTL activity. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 72) Betts MR, Krowka J, Eron J, Sheppard H, Frelinger J |
|
| 73 | Narrowly directed HIV-1-specific CTL responses in rapidly progressive disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 73) Hay C, Ruhl D, Dipasquale MP, D'Aquila R, Walker B |
|
| 74 | Multiple HLA class I, class II and TAP markers collectively predict AIDS-free time in 5 groups of homosexual men. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 74) Keet IP, Tang J, Carrington M, Mann D, Goedert J, Enger C, Kaslow RA |
|
| 75 | Comparison of viral load and HLA statistical and artificial intelligence predictive models for the rate of HIV disease progression. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 75) Ioannidis JP, Goedert JJ, McQueen PG, Enger C, Kaslow RA |
|
| 76 | HIV disease progression and associated genetic markers. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:92 (abstract no. 76) Buchbinder S, Vittinghoff E, Kaslow R, Keet I, O'Brien S, Carrington M |
|
| 77 | Amsterdam Cohort Study: presence of the variant mannose-binding lectin (MBL) alleles associated with slower progression to AIDS? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 77) Maas J, De Roda Husman AM, Brouwer M, Krol A, Coutihno R, Keet I, Schuitemaker H |
|
| 78 | Individual T-cell homeostasis failure and progression to clinical AIDS. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 78) Gange SJ, Munoz A, Chmiel JS, Donnenberg AD, Detels R, Margolick JB |
|
| 79 | Effects of SIV(smm) and STLV(sm)-I dual infection on viral burden and disease progression in pig-tailed macaques. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 79) McGinn TM, Stallworth J, Smith S, Wilson A, Fultz PN |
|
| Session 15— Poster Vaccine Development |
||
| 80 | Humoral immune responses to recombinant HIV-1 envelope antigens in newborns receiving gp120 vaccines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 80) McFarland EJ, Borkowsky W, Wara D, Macnamara J, Kang M, Fenton T, Cunningham C, Mofenson L, Duliege A, Sinangil F, Francis D |
|
| 81 | Safety of recombinant HIV-1 envelope vaccines in neonates born to HIV-1 infected women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:93 (abstract no. 81) Cunningham CK, Wara DW, Fenton T, Kang M, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland E, Borkowsky W |
|
| 82 | Generation of HIV-epitope-specific CTL by HIV-peptide pulsed, allogeneic dendritic cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 82) Raychaudhuri SK, Dupuis M, Benike C, Engleman E, Merigan TC |
|
| 83 | Therapeutic vaccination with p24-VLP and AZT augments HIV specific CTL activity in HIV infected individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 83) Clarkson J, Ffrench R, Law M, Marshall P, Kelleher T, Smith D, Patou G, Stewart G, Cooper D, Benson EM |
|
| 84 | Peptide immunogens representing conserved epitopes of gp120 can induce immune responses recognizing gp120 that are not formed by immunization with whole rgp120. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 84) Kelker HC, Nardelli B, Itri V, Paolino A, Valentine FT |
|
| 85 | Comparative analysis of immune responses to HIV-1 envelope glycoproteins in mice immunized respectively with a DNA vaccine, a recombinant Semliki Forest virus RNA and a recombinant Semliki Forest virus particle. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 85) Brand D, Lemiale F, Buzelay L, Brunet S, Barin F |
|
| 86 | Vaccine evaluation studies of replication-defective SIVsmB7. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 86) Kraiselburd E, Salaman A, Rivera M, Kessler M, Knezevich M, Rodriguez A, Montefiori D, Martinez I |
|
| 87 | Enhancement of anti-HIV T cell responses by delivery of HIV-1 proteins to dendritic cells. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:94 (abstract no. 87) Zheng L, Huang X, Fan Z, Borowski L, Wilson C, Rinaldo C |
|
| 88 | QS21 is superior to alum as an adjuvant with low dose, recombinant MN gp120 for immunization of HIV-1 uninfected volunteers: cellular and humoral responses. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 88) Kallas KG, Evans TG, Gorse G, McElrath MJ, Mulligan M, Matthews T, McNamara J, Wolff M, Francis D |
|
| 89 | Effect of boosting and jet-injection on safety and immune responses in recipients of a DNA-based HIV-1 vaccine. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 89) MacGregor R, Boyer J, Ugen K, Higgins T, Baine Y, Ginsberg R, Weiner D |
|
| Session 16— Poster Immune Correlates of Resistance to Retroviral Infection |
||
| 90 | CD8+ T cells mediate resistance to HIV challenge in SCID mice engrafted with PBL of long term non-progressors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 90) Lopez JC, McNeil AC, Gea-Banacloche JC, Connors M |
|
| 91 | Vaccine induced CTL activity correlates with resistant phenotype in an in vitro challenge system. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:95 (abstract no. 91) Castillo RC, Arango-Jaramllo S, Humphrey W, Weinhold K, Schwartz DH |
|
| 92 | Detection of HIV-specific CTL activity in HIV exposed uninfected subjects. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 92) Yannakis C, Bernard NF, Lee J, Tsoukas CM |
|
| 93 | Correlates of immune protection in sexually exposed HIV seronegative individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 93) Mazzoli S, Lo Palco L, Meacci F, Trabattoni D, Salvi A, Biasin M, Lo Caputo S, Ble C, Semplici F, Siccardi AG, Clerici M |
|
| 94 | Homozygosity for CCR5 deletion (&Delta32;/&Delta32;) explains protection from HIV-1 infection in few very high risk HIV-1 homosexual men. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 94) Detels R, Enger C, Dean M, Carrington M, Zimmerman P, Murphy P, Koup R, O'Brien S, Kaslow R |
|
| 95 | Investigation of CD8 suppression as a mechanism of HIV resistance in highly exposed, persistently seronegative (HEPS) individuals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 95) Pisell TL, Hodge TW, Qari S, McNicholl JM, Bond KB, Limpakarnjanarat K, Mastro TD, Folks TM, Butera ST |
|
| Session 17— Poster Humoral and Cellular Immunity to HIV-1 |
||
| 96 | Binding of monoclonal antibodies (mAb) to intact HIV-1 virions: a new strategy for mapping conserved HIV-1 epitopes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:96 (abstract no. 96) Nyambi PN1, Gorny MK1, Williams C1, Zolla-Pazner S1,2 |
|
| 97 | Antigenic relationships among group M HIV-1 viruses revealed by identification of shared V(3) epitopes. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 97) Gorny MK, Nadas A, Vancott TC, Nyambi PN, Williams C, Zolla-Pazner S |
|
| 98 | Neutralization of several HIV-1 primary isolates by sera from HIV-negative recipients of candidate HIV vaccines Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 98) Zolla-Pazner S, Xu S, Burda S, Dayaraj C, Kewalramani V, Littman D, Clements-Mann ML, Excler JL, Duliege AM |
|
| 99 | Characterization of highly conserved epitopes in the V(1)/V(2) domain of HIV-1 gp120 that mediate potent neutralization of primary HIV-1 isolates. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 99) Pinter A, Burkhart M, Honnen W, Kayman S, Reiken S, Tan G, Trochev O, Wu Z |
|
| 100 | Partial Glycosylation at Asn-X-Ser/Thr Sequons Contributes to Structural Diversity in the V3 Region of HIV-1 gp120 Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 100) Mellquist J1,2, Wunner WH3, Jackson JB1, and Shakin-Eshleman SH1 |
|
| 101 | Passive administration of an anti-HIV-1 monoclonal neutralizing Ab does not modify the course of established HIV-1 infection in the hu-PBL SCID mouse model. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 101) Poignard P, Gulizia R, Picchio G, Wang M, Parren P, Mosier D, Burton D |
|
| 102 | Interactions between domains in gp120 and gp41 determine neutralization sensitivity phenotype of HIV-1 envelope glycoproteins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:97 (abstract no. 102) Park EJ, Theodore TS, Quinnan GV Jr |
|
| 103 | Inactivation of HIV-1 infectivity with preservation of conformational and functional integrity of virion surface proteins. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 103) Rossio JL, Esser MT, Schneider DK, Bess JW Jr, Grimes MK, Arthur LO, Henderson LE, Lifson JD |
|
| 104 | Resistance of primary isolates of HIV-1 to complement mediated lysis. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 104) Takefman D, Sullivan B, Spear G |
|
| 105 | Circulating CD8 T lymphocytes in HIV-infected individuals have impaired function and downmodulate CD3zeta, the signaling chain of the T cell receptor complex. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 105) Trimble LA, Lieberman J |
|
| 106 | Effective lysis of HIV-infected primary CD4 T cells by a CTL clone directed against a novel A2-restricted HIV-1 reverse transcriptase epitope. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 106) Shankar P, Sprang H, Lieberman J |
|
| 107 | CD86 confers and directs and MHC class I restricted CTL induction. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 107) Kim JJ, Agadjanyan MG, Trivedi N, Wilson DM, Morrison LD, Maldonado MA, Williams WV, Weiner DB |
|
| 108 | HIV regulatory gene expression alters the surface density of T-cell receptor-(TCR)/CD3 complexes on a CD4+ T cell line. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:98 (abstract no. 108) Willard-Gallo K, Furtado M, Burny A, Wolinsky S |
|
| Session 18— Poster Miscellaneous Immunology |
||
| 109 | Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays in HIV-infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 109) Weinberg A, Betensky R, Zhang L, Ray G |
|
| 110 | Survival in advanced HIV disease is more stringently related to lymphocyte activation as reflected by expression of elevated CD38 antigen on T cells than to plasma HIV viral burden. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 110) Giorgi JV, Wolinsky SM, Hultin L, Phair JJ, Jacobson L, Detels R |
|
| 111 | Activation of the p38 MAP kinase pathway by lipopolysaccharide (LPS) interferes with HIV-1 infection of monocyte-derived macrophages. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 111) Reiling N, Zybarth G, Bukrinsky M |
|
| 112 | Expression and function of SLAM-positive lymphocytes in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:99 (abstract no. 112) Clerici M, Meroni L, Fusi ML, Varchetta S, Biasin M, De Vries J, Aversa G, Galli M |
|
| Session 19— Poster Diagnostics: Viral Diversity |
||
| 113 | Detection of HIV-2 in specimens submitted for HIV-1 testing in New York City from 1993-1995. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 113) Beatrice ST, Oleszko WR, Torian V, Chiasson MA, Punsalang A, Weisfuse IB, Schable CA |
|
| 114 | A highly sensitive method for HIV-2 DNA amplification. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 114) Damond F, Loussert-Ajaka I, Apetrei C, Descamps D, Souquiere S, Lepretre A, Matheron S, Brun-Vezinet F, Simon F |
|
| 115 | V3 serotyping of HIV-1 infection: correlation with genotyping, limitations and identification of subtype-specific amino-acid sequences. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 115) Plantier JC, Simon F, Peeters M, Kanki PJ, Barin F |
|
| 116 | A rapid assay for the simultaneous detection and differentiation of antibodies to HIV-1 group M, HIV-1 group O and HIV-2. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 116) Vallari A, Varitek V, Necklaws E, Hickman R, Hackett J Jr, Devare S |
|
| 117 | Quantitation of group O and group M subtypes A-H by the Gen-Probe HIV-1 viral load assay. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:100 (abstract no. 117) Sanders M, Gurtler L, Simon F, Bott M, Dise E, Giachetti C, Nunomura K, Bodrug S |
|
| 118 | Sensitive and accurate quantitation of diverse HIV-1 subtypes utilizing the Digene HIV RNA test. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 118) Schiltz H, Tang Y, Glock J, Davis K, Lorincz A, Lazar J, De la Rosa A |
|
| 119 | Sensitivity, linear range and performance on HIV-1 subtypes of the AMPLICOR HIV-1 MONITOR Test, version 1.5 and the ultra-sensitive specimen preparation method. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 119) Herman S, Sun R, Wang J, Debonville D, Payne H, Dreyer K, Lavallee K, Chutoransky L, Arole M, Arch K, Jayakar H, Kuo JC, Ku J, Spadoro J |
|
| 120 | Anti-HIV-1/2 assay with increased detection to group O by addition of group O recombinant antigens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 120) Sullivan M, Finley A, Kite A, Lainio S, Chang CD, Jiang L, Munson S, Mestek A, Shah D, Shumard-Sauer C |
|
| 121 | A simultaneous HPLC assay for quantification of indinavir (IDV), saquinavir (SQV), ritonavir (RTV), and nelfinavir (NLV) in human plasma. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 121) Kawle SP, Remmel RP, Weller D, Fletcher CV |
|
| Session 20— Poster Epidemiology: Molecular Subtypes of HIV |
||
| 122 | Heterogenic distribution patterns of HIV-1 epidemic in Brazil. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:101 (abstract no. 122) Ramos A, Tanuri A, Rayfield MA, Janini LM, Pieniazek D |
|
| 123 | Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 123) Pinto ME, Tanuri A, Schechter M |
|
| 124 | Human immunodeficiency virus type 1 diversity in Romania. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 124) Apetrei C, Necula A, Holm-Hansen C, Duca M, Pecec M, Brun-Vezinet F, Simon F |
|
| 125 | Non-B subtypes of HIV-1 Group M in specimens from New York City between 1993-1995. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 125) Beatrice ST, Oleszko WR, Punsalang A Jr, Chiasson MA, Torian LV, Weisfuse IB, Schable CA |
|
| 126 | Evidence for quadruple recombination between subtypes A, C, G And I in an HIV-1 isolate from Cyprus. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 126) Gao F, Robertson DL, Carruthers CD, Li Y, Salminen M, Kostrikis L, Ho DD, Hahn BH |
|
| 127 | Genomic sequence of HIV-1 group O isolate HAM112. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:102 (abstract no. 127) Golden A, Lund J, Gurtler L, Devare S |
|
| Session 21— Poster Epidemiology: Substance Abuse |
||
| 128 | The increasing impact of injecting drug use (IDU) on the AIDS epidemic, New York City (NYC), the first 100,000 AIDS cases. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 128) McFarland JW, Singh T, Vasquez F, Forlenza S |
|
| 129 | Overlapping AIDS epidemic among injecting drug use (IDU) and heterosexual exposure (HT) in New York City (NYC) AIDS cases. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 129) Chu A, Torbert A, Brown L, Ellison J, Matthew I, McFarland J, Forlenza S |
|
| 130 | Sustained high HIV seroprevalence in crack users attending sexually transmitted disease clinics in New York City, 1990-1996. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 130) Menzies IB, Makki HA, Schween FW, Weisfuse IB, Benson DA, Torian LV |
|
| 131 | Age-specific differences in HIV incidence and risk behaviors among illicit drug users admitted to drug treatment. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 131) Murrill CS, Miller MS, Gwinn M |
|
| 132 | HIV+ IDUs eligible for antiretrovirals: what are the barriers to receiving therapy despite universal access? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:103 (abstract no. 132) Strathdee SA, Palepu A, Cornelisse PG, O'Shaughnessy MV, Schechter MT, Montaner JS, Hogg RS |
|
| 133 | Explosive HIV epidemics in injection drug users - what are the causes and controls? Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 133) Raboud JM, Thorne AK, Strathdee SA, O'Shaughnessy MV, Schechter MT |
|
| 134 | Needle exchange programs: availability and participation among injection drug using women. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 134) Rich JD, Astemborski J, Smith DK, Schoenbaum E, Davenny K, Schuman P, Vlahov D |
|
| Session 22— Poster Epidemiology: Infection Control |
||
| 135 | Passive HIV antibody reactivity following a health care worker (HCW) accident: implications for HCW post-exposure management. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 135) deOliveira CF, Harmache A, Frenkel LM, Gupta P, Mullins JI, Busch MP |
|
| 136 | Postexposure antiretroviral treatment for non-occupational exposure to HIV at Bichat-Claude Bernard Hospital, in Paris. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:104 (abstract no. 136) Bouvet E, Prevot MH, Matheron S, Laporte A |
|
| 137 | Clinical characteristics and HIV serostatus of patients (P) in respiratory isolation in a large urban county hospital. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 137) Denbesten K, Pulvirenti J, Wester W, Ajudia K, Braswell K, de Guzman D, Welbel S |
|
| 138 | HIV seroprevalence in patients being evaluated for tuberculosis (TB). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 138) Welbel S, deGuzman D, Denbesten K, Wester W, Ajudia K, Braswell K, Pulvirenti J |
|
| 139 | Self-assessment of PPD skin test reactions by drug users with or at risk for HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 139) Gourevitch MN, Teeter R, Klein RS &&&Montefiore Medical Center, Bronx, NY |
|
| Session 23 — Poster Epidemiology: Miscellaneous |
||
| 140 | Per-contact risk for transmission of HIV associated with four types of homosexual contact. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 140) Vittinghoff E, Buchbinder SP, Judson F, Douglas J, McKirnan D, MacQueen K |
|
| 141 | Study of acute and early infections yields surprising risk profile. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:105 (abstract no. 141) Senterfitt JW, Harawa NT, Whitfeld C, Kerndt PR, Daar E |
|
| 142 | Changes in HIV seroprevalence in entrants to the New York City correctional system, 1992-1996. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 142) Torian LV, Makki HA, Weisfuse IB |
|
| 143 | Integration and optimization of HIV rapid testing algorithms in client-centered HIV counseling. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 143) Fridlund C, Downing RG, Alwano-Edyegu MG, Otten RA, Marum E, Dondero T, Campbell C, Rayffeld M |
|
| Session 24 — Poster Antiretroviral Therapy: Practice Patterns, Adherence, and Outcomes |
||
| 144 | Recent patterns of antiretroviral therapy (AR) and clinical response in ambulatory HIV patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 144) Moorman A, Delaney K, Palella F, Ashman D |
|
| 145 | Outcomes of triple therapy that included a protease inhibitor (PI) among 2139 patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:106 (abstract no. 145) Fessel WJ, Hurley LB |
|
| 146 | Antiretroviral usage patterns before and after instituting national treatment guidelines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 146) Gruta CL, Liljestrant P, Balano KB, Legg JJ, Dong BJ, Goldschmidt RH |
|
| 147 | 1996 IAS-USA recommendations in clinical practice in Argentina: one year after. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 147) Cahn P, Zala C, Gun A, Maralit J, Perez H, Callegari M, Kauffman S |
|
| 148 | Maintaining protease inhibitor therapy in a clinic setting. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 148) Bozek PS, Perdue BE, Forrest-Smith M |
|
| 149 | Relationship between adherence to HAART and disease state. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 149) Tebas P, Royal M, Fichtenbaum C, Blutman J, Arens M, Horgan M, Powderly W |
|
| 150 | Abstract Withdrawn | |
| 151 | Adherence and effectiveness of protease inhibitors in clinical practice. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 151) Hecht FM, Colfax G, Swanson M, Chesney MA |
|
| 152 | HIV-infected homeless and marginally housed (H/M) patients adhere to and receive early virologic benefit from protease inhibitors (PI). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:107 (abstract no. 152) Bangsberg DR, Zolopa AR, Charlebois E, Tulsky J, Hecht FM, Robertson M, Chesney M, Holodniy M, Merigan TC, Moss AR |
|
| Session 25 — Poster Immunologic Effects of Highly Active Antiretroviral Therapy |
||
| 153 | Improvement in T-cell receptor BV perturbations following combination therapy with indinavir and nucleoside RT inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 153) Jaramillo A, Zaunders J, Kelleher T, Cooper DA |
|
| 154 | Disordering of CD4 and CD8 T-cell repertoires during progression to AIDS and restoration of the CD4 repertoire under antiviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 154) Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C, Karmochkine M, Raguin G, Autran B, Debre P |
|
| 155 | Longitudinal study of cytokine gene expression and TCR Vb repertoire in patients after initiation of ritonavir plus saquinavir therapy (ANRS 069). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 155) Lantz O, Martinon F, Peguillet I, Taoufik Y, Lefebvre P, Bellissant E, Goujard C, Michelet C, Guillet JJ, Delfraissy JF |
|
| 156 | Changes in immunological status of HIV-infected patients receiving triple combination antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 156) Weiss L, Girard PM, Roux A, Ancuta P, Tessey C, Kazatchkine MD, Haeffner-Cavaillon N |
|
| 157 | Reconstitution of "naive" (CD45RA +CD62L +) CD4+ T-cells after potent anti-HIV-1 therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:108 (abstract no. 157) Hengel RL, Jones BM, Kennedy SM, Hubbard MS, McDougal JS |
|
| 158 | Reconstitution of memory (CD45RO) and naive (CD45RA) CD4+ T cells following ritonavir therapy in HIV-infected children with advanced disease. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 158) Sleasman J, Goodenow M, Nelson R, Wilfert D, Hutson A, Heath-Chiozzi M, Pizzo P, Mueller B |
|
| 159 | Downregulation of cytokine production in lymphoid tissue following successful HIV suppressive therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 159) Andersson J, Fehniger T, Patterson BK, Pottage J, Jones P, Landay A |
|
| 160 | Altered cytokine production in patients following institution of highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 160) Siegel JN, Spritzler J, Wade M, Lederman MM, Connick E, Kessler H, Landay AL |
|
| 161 | One year follow-up of CD4 and CD8 cytokine secreting lymphocytes in HIV infected patients treated with stavudine + didanosine + ritonavir. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 161) Levacher M, Bouscarat F, Chau F, Landman R, Gaudebout C, Prevot MH, Damond F, Mathez D, Leibowitch J, Sinet M, Saimot A |
|
| 162 | Immune activation of T-helper cells in lymphoid tissue is associated with viral replication which can effectively be controlled by highly active antiretroviral therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 162) Van Lunzen J, Hufert F, Bosch B, Tenner-Racz K, Racz P, Stellbrink HJ |
|
| 163 | Delayed and sustained immunologic recovery after 15 months of active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:109 (abstract no. 163) Goujard C, Wallon C, Taoufik Y, Lantz O, Delfraissy JF |
|
| 164 | CD8 T cell-mediated suppression of HIV-1 is enhanced in patients receiving stavudine/indinavir therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 164) Wilkinson J, Zaunders J, McQueen P, Delaney S, Cooper DA |
|
| 165 | The effect of potent anti-HIV therapy on circulating and secreted levels of beta chemokines. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 165) Kumar D, Parato K, Kumar A, Sun E, Cameron DW, Angel JB &&&Ottawa General Hospital, Ottawa, Canada |
|
| 166 | Activation and function markers of CD4+ and CD8+ T cells after potent anti-HIV-1 therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 166) Hengel RL, Jones BM, Kennedy SM, Hubbard MS, McDougal JS |
|
| 167 | Correction of immunological disorders with highly active antiretroviral therapies (HAART) of acute HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 167) Carcelain G, Blanc C, Debre P, Mathez D, Saimot AG, Leibowitch J, Autran B |
|
| 168 | Emergence of genotypic resistance in HIV-1 protease in children with reduced virus burden and significant immune reconstitution in response to highly active retrovirus therapy (HAART). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 168) Burkhardt B, Perez EE, Mueller B, Pizzo P, Dunn BH, Sleasman JW, Goodenow MM |
|
| 169 | Highly active antiretroviral therapy (HAART) results in delayed enhancement of CD4+ T cell reactivity to mitogen and recall antigens, but not HIV-1 antigens. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:110 (abstract no. 169) Liebmann I, Huang X, Fan Z, Mellors J, Al-Shboul Q, McMahon D, Riddler S, Day R, Chen W, Bazmi A, Rinaldo C |
|
| 170 | Reduction in B cell hyperactivity during combination therapy for HIV-1 infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 170) Morris L, Binley JM, Clas B, Astill T, Kost R, Hurley A, Talal A, Cao Y, Markowitz M, Ho DD, Moore JP |
|
| 171 | Reversal of immune activation during potent anti-retroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 171) Majchrowicz MA, Hultin LE, Hultin P, Hausner MA, Kaplan A, Johnson T, Detels R, Giorgi JV |
|
| 172 | Long term immune recovery in CD4 and CD8+ T cells with highly active anti-retroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 172) Li TS, Tubiana R, Calvez V, Durali M, Mollet L, Carcelain G, Ait Mohand H, Mathez D, Debre P, Katlama C, Autran B |
|
| 173 | Treatment with highly active antiretroviral therapy (HAART) suggests that T cell depletion in HIV-infected individuals correlates with apoptosis mediated by Fas/FasL interactions. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 173) Dockrell D, Badley A, Ziesmer S, Landay A, Lederman M, Connick E, Kessler H, Kuritzkes D, Lynch D, Roche P, Yagita H, Paya C |
|
| 174 | AICD in CD4 T cells from HIV seropositive patients is proportional to viral load and decreases on combination antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 174) Dockrell D, Badley A, Duffy M, Temesgen Z, Simpson M, Schut R, Yagita H, Lynch D, Leibson P, Paya C |
|
| 175 | Longitudinal analysis of virus specific IgG subclass titres in HIV-1 infected individuals before and during highly active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:111 (abstract no. 175) Hardy G, Imami N, Gazzard B, Gotch F |
|
| 176 | Restoration of neutralizing activity of sera from HIV-infected patients receiving effective antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 176) Nokta M, Turk P, Pollard R |
|
| 177 | Abstract Withdrawn | |
| 178 | Activation and quantitation of latently infected T cells present in HIV-infected patient blood. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 178) Derdeyn CA, Kilby JM, Horton D, Hockett RD, Bucy RP |
|
| Session 26 — Poster Impact of HAART on the Incidence and Spectrum of Opportunistic Complications |
||
| 179 | Changing incidence and spectrum of AIDS-defining illnessess (ADIs) in the modern antiretroviral era. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 179) Forrest DM, Seminari E, Montaner JS, Yip B, Raboud J, Lawson L, Schechter MT, O'Shaughnessy MV, Hogg RS |
|
| 180 | Differences in the incidence rates of opportunistic processes before and after the availability of protease inhibitors. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:112 (abstract no. 180) Michaels S, Clark R, Kissinger P |
|
| 181 | Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 181) Murphy R, El-Sadr W, Cheung T, Luskin-Hawk R, Yurik T, Neaton J, Hafner R; Northwestern University, Chicago, IL |
|
| 182 | Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 182) Costagliola D |
|
| 183 | Decline in specific opportunistic infections (OI) at San Francisco General Hospital (SFGH). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 183) Holtzer CD, Jacobson MA, Hadley WK, Huang L, Stanley HD, Montanti R, Wong M, Stansell JD |
|
| 184 | Decline in CMV and other opportunistic disease with combination antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 184) Moore RD, Keruly JC, Chaisson RE |
|
| 185 | Pneumocystis carinii pneumonia in the protease inhibitor era. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 185) Huang L, Turner J, Swanson M, Holtzer C, Stansell J, Hecht F |
|
| 186 | Protease inhibitors are associated with less neuropsychological impairment in HIV infection. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:113 (abstract no. 186) Ferrando S, Rabkin J, Van Gorp W, McElhiney M |
|
| Session 27 — Poster Epidemiology: Effects of Therapy on Transmission, Disease Progression, and Survival |
||
| 187 | The effect of protease inhibitor therapy and "undetectable" viral load on perceived risk of HIV transmission and need for safer practices. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 187) Kravcik S, Victor G, Houston S, Sutherland D, Garber GE, Foss NH, Angel JB, Badley A, Cameron DW |
|
| 188 | Impact of anti-retroviral therapy on HIV-1 seminal viral load. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 188) Barroso PF, Harrison LH, Souza YC, Bonfim AS, Schechter M, Gupta P |
|
| 189 | Correlates of HIV-1 detection by viral load and culture in semen. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 189) Evans JS, Dolan MJ, Walter EA, Anderson SA, Merritt T, Wegner S; Wilford Hall Medical Center, Lackland, Texas |
|
| 190 | Quantitative HIV-DNA detection in semen of HIV-infected individuals: correlation with HIV-RNA and culture. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 190) Vernazza PL, Dollenmaier G, Gowland PL, Roth F, Eron JJ, Fiscus SA |
|
| 191 | Use of immunological and virological markers and a continuous time Markov model to estimate the effect of multitherapies in a cohort of severe HIV infected patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:114 (abstract no. 191) Le Pen C, Rozenbaum W, Downs A, Wirbel E, Adda N, Lilliu H, Maurel F, Beresniak A; Dauphine University, Paris, France |
|
| 192 | Progression of disease in the Pacific Oaks Population Study (POPS) since the introduction of protease inhibitors and use of highly active antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 192) Shaefer M, Shaker-Irwin L, Maude C, Williams V, Morales D, Thommes J, Graham N |
|
| 193 | Increased survival time to AIDS and death associated with use of combined therapy in the multicenter AIDS cohort study. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 193) Detels R, Munoz A, McFarlane G, Kingsley L, Margolick J, Giorgi J, Schrager L, Phair J |
|
| 194 | Improved survival time and CD4 slope associated with recent advances in HIV antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 194) Rachlis AR, Palmer RW, Doswell M |
|
| 195 | Regional survival differences across Europe in HIV positive patients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 195) Vella S, Chiesi A, Mocroft A, Dally LG, Phillips AN, Miller V, Staszewski S, Lundgren JD |
|
| 196 | Temporal trends in survival for adults diagnosed with AIDS in Massachusetts, 1979-1994. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 196) Gallagher KM, Demaria A, Seage GS, Hereen T |
|
| 197 | Decreased morbidity and mortality among HIV+ individuals following initiation of antiretroviral therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:115 (abstract no. 197) Hogg RS, Yip B, Heath KV, Craib KJ, Schechter MT, O'Shaughnessy MV, Montaner JS |
|
| 198 | Dramatically declining morbidity and mortality in an ambulatory HIV-infected population. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 198) Palella F, Moorman A, Delaney K, Loveless M, Fuhrer J, Aschman D, Holmberg S |
|
| Session 28 — Poster Epidemiology: Effects of HIV-1 Therapy on Cost of Care and Hospitalization |
||
| 199 | Rate of AIDS defining events (ADEs) and resulting cost of care: indinavir (IDV) in combination with zidovudine (ZDV) [or stavudine (d4T)] + lamivudine (3TC) versus ZDV [or d4T] + 3TC. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 199) Cook J, Coplan P, Markson L, Yin D, Meibohm A, Dasbach E, Nguyen BY |
|
| 200 | HAART reduced overall costs of HIV care at DVAMC-Denver. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 200) McCollum M, Klaus B, La Rue R, Bessesen M |
|
| 201 | Impact of aggressive management of HIV infection on clinical outcome and cost of care within a health maintenance organization. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 201) Melnick D, Greiner D, Little P, Melnick K |
|
| 202 | HIV physicians who provide continuity of care decrease the cost of HIV inpatients. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:116 (abstract no. 202) Brown I, Demissie K, Rhoads GG |
|
| 203 | Stabilization of in-patient daily census despite continued reduction in HIV-related admissions at a New York City hospital. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 203) Torres RA, Baney M, Barr MR |
|
| 204 | Decreased hospital utilization and costs are associated with protease inhibitor therapy but not with nucleoside therapy. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 204) Keiser P, Kvanli M, Turner D, Smith JW, Nassar NN, Gregg CR |
|
| 205 | Impact of HAART on rates and types of hospitalization at a New York City hospital. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 205) Paul S, Ziecheck W, Gilbert HM, Jacobs J, Sepkowitz KA |
|
| 206 | Six year improvement in HIV hospital outcomes at Cook County hospital, Chicago: impact of AIDS care units and HAART. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 206) Sherer R, Pulvirenti J, Cohen M, Barker D, Fried M, Jasek J, Dykeman M, Rogers J, Weinstein R |
|
| Session 29 — Poster Epidemiology: Correlates of Disease Progression and Survival |
||
| 207 | Quantitative HIV-1 RNA (RNA) and other factors associated with survival in the women's interagency HIV study (WIHS). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:117 (abstract no. 207) Anastos K, Kovacs A, Kalish L, Hessol N, Delapenha R, Burns D, Weiser B, Cohen M, Meyer W, Bremer J, Melnick S |
|
| 208 | HIV-1 viral burden predicts survival among severely immunosuppressed HIV-1-infected men. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 208) Jacobson LP, Wolinsky S, Detels R, Giorgi J, Margolick J, Riddler S, Phair J |
|
| 209 | A prospective cohort study of HIV disease progression among drug users by gender. Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:118 (abstract no. 209) Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS |
|
| 210 | Survival differences between younger and older HIV positive patients. Conf Retroviruses Op | |